Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer

Xiaohu Ouyang(Stanford University), Jason M. Cox, Michelle Salazar Pérez(Ondine Biopharma (United States)), Robert S. Kania(RG Biopharma (United States)), Om Makwana(Wake Forest University), Subhas J. Chakravorty(RG Biopharma (United States)), Noel Timple(Ondine Biopharma (United States)), Kathryn B. Grandinetti(Ondine Biopharma (United States)), S. Chopade(RG Biopharma (United States)), Sanjeev Thohan(RG Biopharma (United States)), Rowena Suriben(RG Biopharma (United States)), Sean Uryu(Pfizer (United States)), Scott Womble(Ondine Biopharma (United States)), Yuan Ding(Nanjing Agricultural University), Ping Jiang(Nanjing Agricultural University), Toufike Kanouni(Ondine Biopharma (United States)), Tatiana Koudriakova(Janssen (United States)), Shawn K. Pack(RG Biopharma (United States))
Journal of Medicinal Chemistry
June 3, 2025
10.1021/acs.jmedchem.5c00834
Cited by 1

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Phosphatidylserine Vesicles Enable Efficient En Bloc Transmission of Enteroviruses
|Cell|2015|482
VEGF-Induced Vascular Permeability Is Mediated by FAK
|Developmental Cell|2012|339
FAK promotes recruitment of talin to nascent adhesions to control cell motility
|The Journal of Cell Biology|2012|218